Molecular-based method of cancer diagnosis and prognosis
US8715928B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 12, 2010 |
| Grant date | May 6, 2014 |
| Priority date | — |
| Expiry date | Feb 12, 2030 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/56
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A gene profiling signature for diagnosis and prognosis of cancer patients is disclosed herein. In one embodiment, the gene signature includes 32 or 79 cancer survival factor-associated genes. Thus, provided herein is a method of determining the prognosis of a subject with a tumor by detecting expression of five of more cancer survival factor-associated genes in a tumor sample and comparing expression of the five or more cancer survival factor-associated genes in the tumor sample to a control. In some examples, an increase in expression of ABCF1, CORO1C, DPP3, PREB, UBE3A, and PTDSS1 in a tumor sample compared to a control sample indicates poor prognosis. Also provided is a method of treating a patient diagnosed with cancer by administering a therapeutically effective amount of an agent that alters expression or activity of one or more of the disclosed cancer survival factor-associated genes. Further provided are arrays including probes or antibodies specific for a plurality of cancer survival factor-associated genes or proteins.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.